Posts tagged innovation
McGill University and Moderna to expand collaborations with new projects in Lipid Nanoparticle research

McGill University today announced it has signed agreements with ModernaTX, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to support two innovative research projects in the area of lipid nanoparticles (LNPs). LNPs are critical components in mRNA medicines such as vaccines, as they are the primary delivery method of mRNA strands to the target cells.

Read More
CROs - Pillars in Drug Development

A CRO, or contract research organization, is a company that provides, on a contractual basis, services in the biomedical research field. Given their crucial role in the development of new treatments and technologies, as well as their economic importance, BIOQuébec and CATALIS, with financial support from the Ministry of Economy and Innovation, conducted a study of Quebec CROs to chart the sector’s impact and measure its growth, strengths, and needs.

Read More
Aplantex Announces the Composition of Its C-Suite

Aplantex is pleased to announce the composition of the company’s C-suite. "Aplantex is the result of the innovative work of a multidisciplinary team of skilled individuals committed to simplifying and broadening access to the valuable plant-based bioactive molecules that daily impact our health and well-being," states Mr. Charest.

Read More
Domain Therapeutics announces first patient dosed with DT-9081 in phase I clinical study in patients with advanced, recurrent or metastatic solid tumors: the EPRAD study

Domain Therapeutics, a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces that the first patient has been dosed with DT-9081, Domain’s proprietary IO asset, in a first-in-human Phase I study.

Read More
AbCellera and AbbVie Partner to Advance New Antibody Therapies

AbCellera announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. The partnership will leverage AbCellera’s antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications.

Read More
IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL

IMV Inc. today announced positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”) who received at least three previous lines of treatment.

Read More
Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202

MONTREAL (CANADA) – November 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).

Read More
BIOQuébec writes an editorial entitled "Innovation is the foundation for improving healthcare" in the latest edition of the BioLAB Business journal

Quebec is rich in innovative companies that strive to do things differently to bring our knowledge and skills to another level. We were delighted to honor our members Jenthera Therapeutics, Repare Therapeutics, Ventus Therapeutics, KisoJi Biotechnology, Valence Discovery and Modelis who all innovate in the field of life sciences for the development of new therapies.

Read More
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

LAVAL, Québec, May 18, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announced today that the top line results of its pharmacokinetic (PK) bridging study with IV GTX-104, the Company’s lead drug candidate for the treatment of Subarachnoid Hemorrhage (SAH), met all its planned study endpoints. The primary objective of the study was to evaluate the relative bioavailability of IV GTX-104 compared to oral nimodipine in healthy adult male and female subjects, while the secondary objective was to assess its safety and tolerability. The Company plans to submit these results to the US Food and Drug Administration (FDA), along with its proposed study design for the Phase 3 safety study which is on track to start in the second half of 2022. The safety study is expected to be the final step required to seek regulatory approval under the 505(b)(2) regulatory pathway before submitting a New Drug Application to the FDA.

Read More
A Framework for Action to Support Quebec’s Biopharmaceutical Innovations and Bolster Quebec’s Autonomy

BIOQuébec commissioned The JBL Group to produce a comprehensive account of the situation by first, rigorously documenting the Quebec healthcare system’s recommendation process for Quebec-based innovations and secondly, to develop, with industry partners, public policy proposals that would support the Quebec biopharmaceutical industry’s innovations and development. BIOQuébec’s review was prompted by a widespread perception among many members that Quebec-based drugs and biopharmaceutical industry products were unfavourably considered by the Quebec health and social services network.

Read More
Results of the Study on the Integration of Innovations – BIOQuébec Outlines a Framework for Action to Support Quebec’s Biopharmaceutical Innovations and Bolster Quebec’s Autonomy

Bromont (Québec), April 21 2022 — BIOQuébec is pleased to be releasing the results of a study on the integration of Quebec innovations into our healthcare system. It is also suggests courses of action to better support Quebec-based biopharmaceutical innovations during the entire process and strengthen Quebec’s autonomy.

Read More